REGN609.94+0.33%
REGN · US
1j range: 600.66 → 790.81 · per 2026-06-18
Volgende earnings
2026-07-30
over 37d
Recent materieel nieuws
- Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program2026-06-17T10:55
- Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities2026-06-08T02:48
- Regeneron Pharma To Present New Clinical Data And Research From Its Metabolic Disease, Ophthalmology And Rare Disease Pipelines At ADA 86th Scientific Sessions And ENDO 20262026-06-04T07:14
- CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform2026-06-03T08:04
- Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)2026-06-01T14:34
- Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event2026-05-26T12:44
Wil je deze diepte op elke stock die je volgt?
Stockpeek schrijft een daily AI digest op 165+ stocks, weekly theses, earnings briefings, en alerts — voor €19/mnd. Gratis tier beschikbaar.
Geen beleggingsadvies. Stockpeek is een research-tool. AI-geschreven content is informationeel, geen koop/verkoop-aanbeveling. Beleggingsbeslissingen zijn jouw verantwoordelijkheid.